Evidence map›Paper›PMID 40485939›Full record

ArticleFrontiers in psychiatry2025

Assessment of feasibility of actigraphy as a measure of clinical change in response to an experimental interventional treatment in adolescents and adults with autism spectrum disorder.

Matthew Boice, Svetlana Bryant, Matthew Klein, Martine Meyer, Abi Bangerter, Srinivasan Vairavan, Gahan Pandina

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew BoiceNeuroscience, Janssen Research and Development, Titusville, NJ, United States.
Svetlana BryantDepartment of Psychology, Barker Lab, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.
Matthew KleinNeuroscience, Janssen Research and Development, Titusville, NJ, United States.
Martine MeyerNeuroscience, Janssen Research and Development, Titusville, NJ, United States.
Abi BangerterNeuroscience, Janssen Research and Development, Titusville, NJ, United States.
Srinivasan VairavanNeuroscience, Janssen Research and Development, Titusville, NJ, United States.
Gahan PandinaNeuroscience, Janssen Research and Development, Titusville, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The use of actigraphy as a continuous experimental measure of clinical change was explored through a comparison of two clinical studies in autism spectrum disorder (ASD). The data quality, implementation ease, wear compliance, and clinical outcome correlation of actigraphy as a measure were assessed. Methods: Two clinical studies were conducted and used as a basis of comparison: (1) AUT2001, a Phase 2A interventional study in ASD (N=63), and (2) AUT0002, a Phase 0 non-interventional study in typically-developing (TD) participants (N=53). Participants in both studies wore a wrist-based actigraph throughout enrollment. Actigraphy features were identified based on potential clinical relevance and calculated as weekly averages for each participant's study timepoints. Expert review was used to confirm validity of automated sleep/wake period detection. Feature differences were then assessed using Results: Results from both clinical studies were combined during analysis. Actigraphy was shown to be feasible as a measure of longitudinal change in ASD, but with notable challenges in adherence: participant exclusions due to poor wear compliance substantially reduced the size of the final dataset. Despite this limitation, several findings were noted. Significant differences in sleep disturbance were observed at baseline between the ASD and TD populations as measured by physical activity occurring within the defined sleep period. No significant between-group differences were noted in changes from baseline to endpoint in key sleep variables. Caregiver reported sleep quality significantly correlated with actigraphy measures of sleep disturbance. Additional significant correlations were observed between caregiver reported outcomes of self-regulation and actigraphy features measuring daytime physical activity. Finally, potentially relevant correlations with anxiety, social responsiveness, and restricted and repetitive behaviors are reported. Conclusions: The observed correlations suggest there may be alignment between some generalized features of actigraphy and core and associated domains of ASD. The clinical utility of actigraphy as a biomarker of clinically relevant outcomes in ASD requires further study. Actigraphy may provide supportive evidence of treatment outcome, providing clinical context, or as a objective behavioral measure (e.g., of sleep or activity level) when combined with more traditional clinical outcome measures.

Indexed as

actigraphyautism spectrum disorderbiomarkerclinical trialsfeasibilityoutcome measurement

Identifiers

PMID40485939
PMCPMC12143325

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.